• CSPC Pharmaceutical Group announced on November 2, 2026, the launch of a Phase I trial in China for RSV vaccine SYS6057.
• The trial will assess safety and immune response in adults aged 18 or older; participant recruitment and screening are underway.
• Chinese regulators cleared the clinical trial in July 2026; the study is randomized, blinded and placebo-controlled.
• SYS6057 targets lower respiratory tract disease caused by RSV infection.
• Preclinical results reported in the announcement showed protection against both RSV subtypes, strong neutralizing antibody activity and durable immune protection.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261102-12395193), on November 02, 2026, and is solely responsible for the information contained therein.